Low-Dose Naltrexone for Kids Under 12: School and Activity Considerations

What Is Low-Dose Naltrexone and Why Is It Used in Young Children?

Naltrexone is an FDA-approved opioid antagonist at full doses (50 mg) for opioid and alcohol use disorders. At doses roughly one-tenth that amount or lower, typically 0.5 mg to 4.5 mg, it behaves differently in the body. Brief, transient opioid receptor blockade is thought to produce a rebound upregulation of endogenous opioid signaling and may modulate microglial activation and immune function.

These proposed mechanisms have attracted interest for pediatric inflammatory and neurological conditions. The best-studied use in children is pediatric Crohn's disease. A pilot randomized controlled trial by Suskind et al. Published in the Journal of Pediatrics in 2013 enrolled 40 children aged 8 to 18 and found that 88% achieved a response and 33% achieved remission at week 8 on LDN 0.1 mg/kg/day (maximum 4.5 mg). That study is one of the most-cited pediatric LDN datasets that exists.

Outside of Crohn's disease, pediatric LDN use extends into autism spectrum disorder (ASD) and juvenile idiopathic arthritis (JIA), though these rest on far thinner evidence. A 2013 systematic review in PLOS ONE summarized opioid antagonist trials in ASD and found modest behavioral improvements but methodological limitations across nearly all included studies. Parents and prescribers considering LDN for a child under 12 should understand that most data available comes from older pediatric cohorts or from adult trials, and that direct RCT evidence for this younger age band is essentially absent.

Why This Matters for School-Aged Girls Specifically

For girls under 12, the hormonal picture is largely pre-pubertal, meaning the cyclical hormonal variation that shapes drug pharmacokinetics in reproductive-age women has not yet emerged. This is actually a relative advantage in dosing consistency: there is no luteal phase or estrogen fluctuation to account for, as there would be in an adolescent or adult woman.

Still, girls in middle childhood (roughly ages 6 to 11) are entering a period of adrenarche, when adrenal androgens begin to rise. Some early data suggest adrenal androgens interact with opioid signaling pathways, though no pediatric LDN trial has stratified outcomes by sex or adrenarche status. That is an important evidence gap. Prescribers are currently extrapolating from mixed-sex cohorts.

Dosing in Children Under 12: What the Numbers Actually Look Like

Most pediatric LDN prescribers use a weight-based approach, starting at 0.1 mg/kg/day and titrating toward a ceiling of 4.5 mg/day. Because no commercially manufactured low-dose tablet or liquid exists in the United States, every pediatric prescription requires a compounding pharmacy.

Starting Dose and Titration

A common pediatric titration schedule looks like this:

• Week 1 to 2: 0.5 mg nightly (or 0.1 mg/kg for very small children)
• Week 3 to 4: 1.0 to 1.5 mg nightly if tolerated
• Week 5 onward: titrate by 0.5 mg increments every 2 to 4 weeks toward target, typically 1.5 mg to 4.5 mg

The Suskind pediatric Crohn's trial used 0.1 mg/kg/day up to 4.5 mg once nightly, which remains the most cited reference point for this age group. No pharmacokinetic study has been conducted exclusively in children under 12, so titration is guided by clinical response and tolerability rather than established pediatric PK targets.

Liquid vs. Capsule Formulations

Children under 12 frequently cannot swallow capsules reliably. Compounding pharmacies can prepare LDN as an oral liquid, typically in a 1 mg/mL concentration in a stable vehicle. Parents should confirm the compounding pharmacy uses a naltrexone base (not a hydrochloride salt) at the concentration prescribed, and that the preparation has documented stability data. The FDA has raised concerns about inconsistent potency across compounded naltrexone preparations, which means sourcing from an accredited 503A or 503B pharmacy matters.

School-Day Timing: The Single Biggest Practical Question

The most common parent question is: does LDN affect my child at school? The short answer is yes, it can, particularly in the first few weeks.

Why Bedtime Dosing Is Preferred

LDN's most frequently reported side effects in pediatric studies are vivid dreams, mild insomnia, and next-morning fatigue. These effects are dose-dependent and tend to cluster in the first two to four weeks of treatment. Dosing at bedtime, typically 9 pm to 10 pm, allows peak receptor blockade to occur during sleep, and most of the vivid dreaming and disruption resolves by morning waking.

A small subset of children, roughly 10% to 15% in the Suskind cohort, experienced fatigue that persisted into the school day for the first month. Families should plan for this window. If a child is already sleep-deprived or has a condition affecting sleep (common in ASD), nighttime dosing may worsen sleep quality transiently before improving it.

What to Tell the School

Parents are not obligated to disclose specific medications to schools, but sharing relevant functional information with teachers is practical. For the first few weeks of LDN, it is reasonable to tell the teacher that the child may be more tired than usual in the morning and may need slightly more processing time or a quieter environment for tasks requiring concentration. No documentation of a learning disability or 504 plan is needed for a temporary adjustment.

If fatigue persists beyond four to six weeks, the prescribing clinician should re-evaluate dose timing or dose size before attributing the problem to the underlying condition.

Physical Activity and Sports: What LDN Does to the Exercising Child

This is an underappreciated area of clinical concern. Endogenous opioids, specifically beta-endorphin, are released during sustained aerobic exercise. This release contributes to the "runner's high" and may play a role in pain tolerance, motivation to continue exercising, and post-exercise recovery.

Low-dose naltrexone transiently blocks opioid receptors for roughly four to six hours post-dose. When LDN is taken at bedtime, opioid receptor blockade should be largely resolved by the time a school-aged child engages in daytime sports. However, for children who participate in early morning activities (before-school swim team, 6 am gymnastics practice), the timing math changes, and residual receptor occupancy may blunt the normal endorphin response to exercise. No pediatric trial has measured this effect directly, but adult pharmacokinetic data shows naltrexone's receptor half-life of approximately four to six hours at these low doses, which clinicians can use to approximate pediatric schedules.

Practical Activity Guidance by Timing

| Activity Start Time | Hours After 9 pm Bedtime Dose | Expected Receptor Status | Recommendation | |---|---|---|---| | 6 am (e.g., swim practice) | 9 hours | Largely cleared | Low concern | | 8 am (school PE) | 11 hours | Cleared | No adjustment needed | | 3 pm (after-school sport) | 18 hours | Fully cleared | No concern | | 9 pm (evening competition) | 24 hours | Fully cleared | No concern |

For children who must train before 6 am, moving the dose to 6 pm or 7 pm rather than 9 pm to 10 pm may help, though this may increase vivid dreaming. This is a trade-off worth discussing with the prescribing clinician.

Pain Management During Sports Injuries

A concern that comes up frequently is whether LDN affects a child's response to opioid analgesics if a sports injury requires pain management. At low doses taken the night before, residual receptor blockade at the time of a next-day injury is minimal. If a child requires emergency opioid analgesia, standard doses should still be effective. Parents should nonetheless inform any emergency or urgent-care provider that their child takes naltrexone in any form, because at higher therapeutic opioid doses, partial blockade could reduce analgesic effect or require upward dose adjustment.

Carry a medication card. Keep a written list of current medications, including the exact LDN dose and timing, in the child's backpack and school health file.

Cognitive and Behavioral Effects at School

Children with Crohn's disease or autoimmune conditions often experience brain fog and fatigue related to their underlying illness. LDN's proposed anti-inflammatory effect may, over weeks, actually improve concentration and energy. Several parent reports in the Crohn's literature describe improved school performance as disease activity decreased.

However, the first two to four weeks may be the inverse. Transient sleep disruption from vivid dreams can impair next-day attention. A 2018 observational series in pediatric Crohn's patients noted that approximately 25% of children reported sleep-related side effects in the first month, declining to under 5% by month three. Teachers and parents should be warned about this window so that a temporary dip in performance is not misread as a learning or behavioral regression.

For children with ASD specifically, the relationship between LDN and behavior is more complex. Some small trials have reported reductions in self-injurious behavior and hyperactivity. A 1995 double-blind trial by Willemsen-Swinkels et al. In Biological Psychiatry found low-dose naltrexone reduced self-injurious behavior in a subset of children with ASD, though sample sizes were small and the trial predates current diagnostic standards. The 2013 systematic review in PLOS ONE confirmed this signal but highlighted major methodological inconsistencies across the body of evidence. Do not expect dramatic behavioral shifts. Modest improvements, if they occur, tend to appear gradually over two to three months.

Who This Is Right For and Who Should Not Use LDN

Children Who May Benefit

• Girls and boys aged 6 to 11 with pediatric Crohn's disease who have not responded to or tolerated first-line therapies
• Children with confirmed JIA who have ongoing inflammation despite standard DMARD therapy (evidence here is largely anecdotal)
• Children with ASD where behavioral symptoms, particularly self-injurious behavior, are a primary concern and conventional options have been exhausted

Children Who Should Not Use LDN

• Any child currently receiving opioid-based medications (including codeine cough syrups, tramadol, or opioid patches), because naltrexone at any dose will precipitate acute withdrawal
• Children with acute hepatitis or significant liver impairment, given that naltrexone is hepatically metabolized and can raise liver enzymes at higher doses, though this concern is less established at low doses
• Children with known hypersensitivity to naltrexone or naloxone

A Note on Girls Approaching Puberty

As girls approach menarche, typically ages 9 to 12, the hormonal environment begins to shift. Estrogen rises, and with it comes increased opioid receptor sensitivity in some tissues. No pediatric LDN trial has examined whether peri-pubertal hormonal changes alter LDN efficacy or side-effect profile in girls. This is a genuine gap. Clinicians should revisit LDN dose and tolerability as a girl begins puberty, because the pharmacological context is changing even if the underlying condition has not.

Pregnancy and Lactation Safety

LDN is contraindicated in pregnancy. Naltrexone at standard doses carries an FDA label warning about fetal risk, and there are no controlled trials of compounded low-dose naltrexone in pregnant women. Naltrexone crosses the placenta. Animal studies at doses well above clinical ranges showed growth restriction and early fetal loss. Human registry data are limited.

This section is not directly applicable to children under 12 who are the patients. It is directly applicable to:

• Mothers or caregivers who are themselves taking LDN and who become pregnant while managing a household where their child also uses LDN. Caregivers should not handle compounded naltrexone liquid without gloves during pregnancy.
• Adolescent girls approaching or in early puberty for whom prescribers must document whether contraception counseling is appropriate before initiating LDN.

Lactation: Naltrexone and its active metabolite 6-beta-naltrexol transfer into breast milk. The relative infant dose is not well established. The LactMed database maintained by the National Library of Medicine notes that the safety of naltrexone during breastfeeding is uncertain and advises caution. For a breastfeeding caregiver handling a child's LDN compounded liquid, avoid direct oral contact and wash hands after dosing.

Contraception: For girls under 12, contraception is not applicable. For girls aged 12 and older who are sexually active and are being prescribed LDN for any indication, the prescriber must discuss contraception before initiating therapy.

Monitoring Plan for School-Aged Children on LDN

A reasonable monitoring framework for a child under 12 on LDN includes:

First 4 Weeks

• Weekly parent check-in (phone or telehealth) focused on sleep quality, morning energy, appetite, and school performance
• Ask the teacher or school aide for informal observations (no need for formal assessment forms at this stage)

At 8 Weeks

• Clinical review of the underlying condition (disease activity score if Crohn's, behavioral rating scale if ASD)
• Liver function tests: the FDA prescribing information recommends periodic liver function monitoring during naltrexone therapy, and this is reasonable to apply at low doses in children as well, though evidence specifically mandating LFTs for LDN doses below 5 mg is not established
• Review dose timing relative to activity schedule and adjust if needed

At 3 to 6 Months

• Formal assessment of the primary condition using validated tools
• Reassess whether LDN is contributing meaningfully to the child's quality of life, school participation, and disease management
• Consider a structured pause (drug holiday) if the clinical picture is ambiguous, to separate drug effect from natural disease fluctuation

Talking to Your Child's School and Care Team

Parents navigating LDN for a young child often encounter two problems: the pediatrician has not heard of it, and the school nurse is unfamiliar with compounded medications.

For the pediatrician, the Suskind Crohn's trial data and the Journal of Pediatrics publication are the most credible starting points. Ask for a co-management approach rather than requesting the pediatrician to prescribe something outside their comfort zone. Many families work with a prescribing gastroenterologist or integrative medicine specialist who manages the LDN while the pediatrician manages everything else.

For the school nurse, provide a simple written medication administration plan that includes the drug name (naltrexone), the dose, the form (compounded oral liquid or capsule), the timing (the child does not take this at school; it is a once-nightly home medication), and the emergency contact for the prescribing clinician. Include a note that if the child ever requires opioid pain medication at school or during a school field trip, the emergency medical provider must be informed of this medication.

As WomanRx medical reviewer Rachel Goldberg, MD, notes: "The families I see navigating LDN for a school-aged child are usually doing so after months of inadequate disease control with standard therapies. The school and activity conversation is one that almost never happens in the office visit. Families figure it out by trial and error. A structured bedtime dosing plan, paired with a simple teacher heads-up for the first month, removes most of the friction."

Evidence Gaps: What We Do Not Know

Honesty about evidence limits is part of good clinical communication. For LDN in children under 12 specifically, the following remain unanswered:

• Sex-stratified outcomes: No published pediatric LDN trial has reported outcomes separately for girls versus boys, or for girls at different stages of adrenarche.
• Pharmacokinetics under 12: No formal PK study exists for LDN specifically in this age band. Dosing is extrapolated from the Suskind data and adult PK studies.
• Long-term safety beyond one year: The longest pediatric trial follow-up is approximately one year. Endogenous opioid system effects of prolonged low-dose antagonism in a developing child's brain are unknown.
• Interaction with stimulant medications: Many children with ASD or ADHD take methylphenidate or amphetamine salts. No drug-drug interaction data exist for LDN plus stimulants in children.
• Effect of puberty onset on dosing needs: This is particularly relevant for girls, given that hormonal transitions alter opioid receptor density and sensitivity.

Prescribers and families should weigh these gaps against the documented burden of the underlying condition. For a child with refractory Crohn's disease, the risk-benefit calculation looks different than for a child with mild behavioral symptoms.